Clinical Decompensation and Outcomes in Patients With Compensated Cirrhosis and a Hepatic Venous Pressure Gradient ≥20 mm Hg
- 21 May 2020
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 115 (10) , 1624-1633
Abstract
INTRODUCTION: Hepatic venous pressure gradient (HVPG) of ≥10 mm Hg predicts clinical decompensation (CD) in compensated cirrhosis. A proportion of cirrhotic patients at presentation have high HVPG (≥20 mm Hg) and are compensated. The natural history, spectrum of CD, and mortality in this group is largely unknown. METHODS: Consecutive compensated cirrhotic patients with HVPG ≥6 mm Hg (n = 741) were followed up for 3–6 months for the development of any CD. Patients were classified based on the baseline HVPG (6 to P < 0.001). First CD was seen earlier (1.3 ± 0.7 years vs 1.5 ± 0.6 years and 1.6 ± 0.5 years, P = 0.02) and more frequently (44.7% vs 11% and 31.1%, P < 0.01) in high HVPG groups compared with low and intermediate HVPG groups, with higher mortality rates. Patients in the high HVPG group compared with the low HVPG group more often had NASH-cirrhosis (35.5% vs 19.6%; P 0.001), higher liver stiffness values (45.06 ± 20.46 vs 20.09 ± 5.47 kPa, P < 0.001), and lower platelet counts (113.37 ± 72.57 vs 151.7 ± 87.30/cmm, P < 0.001). Patients with HVPG ≥12 mm Hg received carvedilol, and a repeat HVPG performed in a proportion after 9.3 ± 2.4 months showed response (≥20% reduction in HVPG or Gr. C, 22.2%, P < 0.05). Baseline HVPG (HVPG ≥12 to P < 0.001) independently predicted CD. DISCUSSION: HVPG ≥20 mm Hg in patients with compensated cirrhosis independently predicts early and more frequent CD and poor outcomes. These patients should be labeled as “high-risk compensated cirrhosis,” and early and effective interventions to reduce portal pressure should be initiated to improve long-term outcomes.Keywords
This publication has 21 references indexed in Scilit:
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaEuropean Journal of Cancer, 2012
- Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertensionJournal of Gastroenterology, 2011
- The clinical use of HVPG measurements in chronic liver diseaseNature Reviews Gastroenterology & Hepatology, 2009
- Acute Hemodynamic Response to β-Blockers and Prediction of Long-term Outcome in Primary Prophylaxis of Variceal BleedingGastroenterology, 2009
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006
- Beta-Blockers to Prevent Gastroesophageal Varices in Patients with CirrhosisNew England Journal of Medicine, 2005
- Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleedingHepatology, 2004
- Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998Hepatology, 2002
- The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enoughHepatology, 2002
- Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilatorsJournal of Hepatology, 1985